September 23rd 2024 Shorla Oncology at CPHI Milan Join us at CPHI 2024 in Milan from 8th – 10th October. We look forward to meeting you. Read more.
FDA Approves Tepylute for Breast and Ovarian Cancer TreatmentJuly 2nd 2024Read More FDA Approves Tepylute for Breast and Ovarian Cancer Treatment
FDA approves Shorla Oncology’s TEPYLUTE for cancer treatmentJuly 2nd 2024Read More FDA approves Shorla Oncology’s TEPYLUTE for cancer treatment
Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian CancerJuly 2nd 2024Read More Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer